Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report

Maurie Markman, Karen A. Iseminger, Kenneth D. Hatch, William T. Creasman, Willard Barnes M, Brent Dubeshter

Research output: Contribution to journalArticlepeer-review

144 Scopus citations


There is a critical need to find additional effective therapies in the management of ovarian cancer. A previously reported Gynecologic Oncology Group trial demonstrated that tamoxifen is an active drug when used in the salvage setting in this malignancy. Unfortunately, this original report did not specifically examine the utility of tamoxifen in patients with clinically defined platinum-refractory disease. In this reanalysis of the results of treatment of 102 evaluable patients entered into this multi-institutional trial, an objective response rate of 13% (95% confidence interval, 6.422.6%) was observed in patients with cisplatin-refractory ovarian cancer. The median response duration in this patient population was 4.4 months (range 1.2-9.2 months). Although the response rate is modest, this well-tolerated hormonal agent is a reasonable therapeutic option in selected patients with ovarian cancer when salvage therapy is to be considered. A possible role for this hormonal agent in other clinical settings in ovarian cancer will need to be defined through the conduct of carefully designed randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)4-6
Number of pages3
JournalGynecologic oncology
Issue number1
StatePublished - Jul 1996
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Tamoxifen in platinum-refractory ovarian cancer: A Gynecologic Oncology Group ancillary report'. Together they form a unique fingerprint.

Cite this